Clinical Trial Update: Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating an investigational Parkinson's disease therapy in patients not well controlled on L-dopa has completed, with sponsor GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Investigational Parkinson's Disease Therapy (unnamed)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED